AstraZeneca: Targeted lung cancer drug Teresa? Indications for first-line combined chemotherapy for advanced non-small cell lung cancer with EGFR mutation approved in China
我放心你带套猛
发表于 2024-6-26 15:36:13
222
0
0
According to AI News, AstraZeneca announced on June 26 that the National Medical Products Administration of China officially approved Teresa& on June 18, 2024; reg; The combination of pemetrexed and platinum based chemotherapy drugs is a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) displacement mutation, commonly known as TAGRISSO® or commonly known as ositinib mesylate tablets.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Boeing has discovered defects in 737 Max bolts, and FAA is closely monitoring targeted inspections
- Baishime Squibb's original albumin paclitaxel has been approved as a new indication in China
- Innovation Drug Enterprises on the Science and Technology Innovation Board Welcoming a Harvest Year: Baekje Shenzhou PD-1 New Indications Accepted by FDA
- JAK1 inhibitor Xibico? New indications for age expansion approved in China
- BeiGene Terezumab has been approved by the European Commission for the treatment of non-small cell lung cancer
- Anjin small cell lung cancer treatment drug approved by FDA: can reduce tumor size and prolong lifespan
- Dialogue with Qian Jing, Vice President of Jingke Energy: Market oriented ability is crucial for the third and fourth quarters of the industry to show signs of recovery
- AstraZeneca lung cancer targeted drug Teresa has been approved for new indications in China
- AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
